TECregen Appoints Dr. Klaas P. Zuideveld as CEO to Lead Thymus Regeneration Platform

TECregen announced the appointment of Dr. Klaas P. Zuideveld, Ph.D., as Chief Executive Officer on January 29, 2026, in Basel, Switzerland.1

Dr. Zuideveld has over 20 years of experience in drug development, translational strategy, clinical development, and regulatory execution across pharma and biotech.1 3

He will lead TECregen’s strategy to advance thymopoietic biologics that rejuvenate thymic epithelial cells (TECs) and restore immune function toward clinical development.1 2

The appointment follows a CHF 10 million (approx. €11M) seed financing led by Boehringer Ingelheim Venture Fund and others, plus Dr. Bo Rode Hansen as Chairman.1 3

TECregen focuses on thymus rejuvenation for conditions like impaired T-cell responses, immune recovery post-therapy, and cancer immunotherapy.1

Sources:

1. https://www.tecregen.com/news/tecregen-appoints-drug-development-veteran-dr-klaas-p-zuideveld-chief-executive-officer-lead-thymus-regeneration-platform-clinic

2. https://discover-pharma.com/tecregen-appoints-zuideveld-ceo-thymus-regeneration/

3. https://trial.medpath.com/news/45f612b5a55ace81/tecregen-secures-eur11m-seed-funding-and-appoints-new-ceo-to-advance-thymus-regeneration-therapeutics

Sources:

Leave a Reply Cancel reply